Farias G. A, Guzman-Martinez L, Delgado C, Maccioni
R. B. Nutraceuticals: a novel concept in prevention and treatment of Alzheimer’s disease and related disorders. J Alzheimer’s Dis 2014; 42(2):357-367. doi: 10.3233/ JAD-132741
Ganesh V, Hettiarachchy NS. Nutriproteomics: a promising tool to link diet and diseases in nutritional research. Biochim Biophys Acta Proteins Proteomics 2012; 1824(10):1107-1117. doi:10.1016/ j.bbapap.2012.06.006
Ma Y, Yang MW, Li XW, Yue JW, Chen JZ, Yang MW, et al. Therapeutic effects of natural drugs on Alzheimer’s disease. Front Pharmacol 2019; 10:1355. doi:10.3389/ fphar.2019.01355
Scheltens P, Blennow K, Breteler MM, de Strooper, B, Frisoni, GB, Salloway, S, et al. Alzheimer’s disease. Lancet 2016; 388: 505–517. doi:10.1016/ S0140- 6736(15)01124-1
Von Gunten A, Bouras C, Kövari E, Giannakopoulos P, Hof P. R. Neural substrates of cognitive and behav- ioral deficits in atypical Alzheimer’s disease. Brain Res Rev 2006; 51(2):176-211. doi:10.1016/j.brainres- rev.2005.11.003
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Bio- chem Pharmacol 2014; 88(4):640-651. doi:10.1016/j. bcp.2013.12.024]
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. 1997. JAMA. doi: 10.1001/jama.1997.03550160069041
Saunders AM, Strittmatter WJ, Schmechel D, St. George- Hyslop PH, Pericak-Vance MA, Joo SH. Association of apolipoprotein E allele E4 with late onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43:1467- 1472. doi:10.1212/WNL.43.8.1467
Hebert L. E, Bienias J. L, Aggarwal N. T, Wilson R. S, Bennett D. A, Shah R. C, et al. Change in risk of Alzhei- mer disease over time. Neurology 2010; 75(9):786-791. doi:10.1212/WNL.0b013e3181f0754f
Hebert L. E, Weuve J, Scherr P. A, Evans D. A. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013; 80(19):1778-1783. doi: https://doi.org/10.1212/WNL.0b013e31828726f5
Fratiglioni L, Ahlbom A, Viitanen M, Winblad, B. Risk
factors for late–onset Alzheimer’s disease: A popula- tion-based, case-control study. Annals Neurol 1993; 33(3):258-266. doi: 10.1002/ana.410330306
Green R. C, Cupples L. A, Go, R, Benke, K. S, Edeki, T, Griffith, P. A, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002; 287(3):329-336. doi: 10.1001/ jama.287.3.329
Pereira CF, Santos AE, Moreira PI, Pereira AC, Sousa FJ, Cardoso SM, et al. Is Alzheimer’s disease an in- flammasomopathy? Ageing Res Rev 2019; 56:100966. doi:10.1016/j.arr.2019.100966
DeTure MA, Dickson DW. The neuropathological di- agnosis of Alzheimer’s disease. Mol Neurodegen 2019; 14(1):1-18. doi:10.1186/s13024-019-0333-5
Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, Ferguson S. M. Massive accumula- tion of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques. Proc Nat Acad Sci USA 2015; 112(28):E3699-E3708. doi:10.1073/ pnas.1510329112
Irvine GB, El-Agnaf, O. M, Shankar, G. M, Walsh DM. Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases. Mol Med 2008; 14(7):451-464. doi: https://doi.org/10.2119/2007-00100. Irvine
Cedernaes J, Schiöth, H. B, Benedict C. Efficacy of antibody-based therapies to treat Alzheimer’s disease: Just a matter of timing?. Experimental gerontol- ogy. 2014; 57:104-106. doi: https://doi.org/10.1016/j. exger.2014.05.002
Ganjei J. K. Targeting amyloid precursor protein secretases: Alzheimer’s disease and beyond. Drug news & perspectives. 2010; 23(9):573-584. doi: 10.1358/ dnp.2010.23.9.1507297
Rosenblum W. I. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, incon- sistent, and difficult. Neurobiology of aging. 2014; 35(5):969-974. doi: https://doi.org/10.1016/j.neurobio- laging.2013.10.085
Huang C, Dong, D, Jiao, Q, Pan, H, Ma, L, Wang R. Sar- sasapogenin–AA 13 ameliorates Aβ-induced cognitive deficits via improving neuroglial capacity on Aβ clear- ance and antiinflammation. CNS Neurosc Ther 2017; 23(6):498-509. doi: https://doi.org/10.1111/cns.12697
Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann, N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatr 2010; 68(10):930- 941. doi: https://doi.org/10.1111/cns.12697
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole,
G. M, Wyss–Coray T, et al. Inflammation and Alzhei- mer’s disease. Neurobiol Aging 2000; 21(3):383-421. doi: https://doi.org/10.1016/S0197-4580(00)00124-X
Lee Y. J, Han S. B, Nam S. Y, Oh, K. W, Hong, J. T. Inflammation and Alzheimer’s disease. Archives of phar- macal research. 2010; 33(10):1539-1556. doi: https://doi. org/10.1007/s12272-010-1006-7
Park M. H, Lee M, Nam G, Kim M, Kang J, Choi B. J, Lim M. H, et al. N, N′-Diacetyl-p-phenylenediamine restores microglial phagocytosis and improves cogni- tive defects in Alzheimer’s disease transgenic mice. Proceedings of the National Academy of Sciences. 2019; 116(47):23426-23436. doi: https://doi.org/10.1073/ pnas.1916318116
Ji K, Akgul G, Wollmuth L. P, Tsirka S. E. Microglia actively regulate the number of functional synapses. PloS one. 2013; 8(2): 56293. doi:10.1371/journal. pone.0056293
Heneka M. T, Carson M. J, El Khoury J, Landreth
G. E, Brosseron F, Feinstein D, Kummer M. P, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14(4):388-405. doi:10.1016/S1474- 4422(15)70016-5
Heppner F. L, Ransohoff R. M, Becher B. Immune at- tack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16(6):358-372. doi:10.1038/nrn3880
Nizami S, Hall-Roberts H, Warrier S, Cowley S. A, Di Danie E. Microglial inflammation and phagocytosis in Alzheimer’s disease: Potential therapeutic targets. Br J Pharmacol 2019; 176(18):3515-3532. doi:10.1111/ bph.14618
Du L, Zhang Y, Chen Y, Zhu J, Yang Y, Zhang, H. L. Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol Neurobiol 2017; 54(10):7567-7584. doi:10.1007/s12035-016-0245-0
Labzin L. I, Heneka M. T, Latz, E. Innate immu- nity and neurodegeneration. Annual Rev Med 2018; 69:437-449. doi: https://doi.org/10.1146/annurev- med-050725-104343
dos Santos G, Kutuzov M. A, Ridge K. M. The inflam- masome in lung diseases. Am J Physiol Lung Cell Mol
Physiol 2012; 303(8):L627-L633. doi:10.1146/annurev- med-050725-104343
Heneka M. T, Kummer M. P, Latz E. Innate immune ac- tivation in neurodegenerative disease. Nat Rev Immunol 2014; 14(7):463-477. doi:10.1152/ajplung.00225.2012
Domijan A. M, Kovac S, Abramov A. Y. Lipid peroxi- dation is essential for phospholipase C activity and the inositol-trisphosphate-related Ca2+ signal. J Cell Sci 2014; 127(1):21-26. doi:10.1038/nri3705
Turillazzi E, Neri M, Cerretani D, Cantatore S, Frati P, Moltoni L, Fineschi V, et al. Lipid peroxidation and apoptotic response in rat brain areas induced by long- term administration of nandrolone: the mutual cross- talk between ROS and NF-kB. J Cell Mol Med 2016; 20(4):601-612. doi: 10.1242/jcs.138370
Chowdhury S, Sinha K, Banerjee S, Sil P. C. Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses. Biofactors 2016; 42(6):647-664. doi:10.1111/jcmm.12748
Saha S, Sadhukhan P, C Sil P. Genistein: a phytoestrogen with multifaceted therapeutic properties. Mini Rev Med Chem 2014; 14(11):920-940. doi:10.1002/biof.1301
Sadhukhan P, Saha S, Dutta S, Mahalanobish S, Sil P.
C. Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer’s disease. Phar- macol Res 2018; 129:100-114. doi:10.2174/138955751 4666141029233442
Ko SY, Lin YP, Lin YS, Chang SS. Advanced glyca- tion end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radical Biol Med 2010; 49(3):474-480. doi:10.1016/j. phrs.2017.11.028
Shi Z. M, Han Y. W, Han X. H, Zhang K, Chang Y. N, Hu, Z. M, Hong W, et al. Upstream regulators and downstream effectors of NF-κB in Alzheimer’s disease. J Neurol Sci 2016; 366:127-134. doi:10.1016/j.freerad- biomed.2010.05.005
Kaur U, Banerjee P, Bir A, Sinha M, Biswas A, Chakra- barti S. Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer’s disease: The NF-κB connection. Curr Topics Med Chem 2015; 15(5):446- 457. doi: https://doi.org/10.1016/j.jns.2016.05.022
Wang X, Wang W, Li L, Perry G, Lee H. G, Zhu X. Oxidative stress and mitochondrial dysfunction in Alz- heimer’s disease. Biochim Biophys Acta Mol Basis Dis 2014; 1842(8):1240-1247. doi: 10.2174/15680266156 66150114160543.
Lu M. A, Rajanala S, Mikkilineni S. V, Cahill C. M, Brown R, Berry J. D, Rogers J. T. The 5’-untranslated region of the C9orf72 mRNA exhibits a phylogenetic alignment to the cis-aconitase iron-responsive element; novel therapies for amytrophic lateral sclerosis. Neurosci Med 2016; 7(01):15. doi:10.1016/j.bbadis.2013.10.015
Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol 2014; 13(3):319-329. doi: 10.4236/nm.2016.71003
Cheng Z, Shang Y, Gao S, Zhang T. Overexpression of U1 snRNA induces decrease of U1 spliceosome function associated with Alzheimer’s disease. J Neurogenet 2017; 31(4):337-343. doi:10.1016/S1474-4422(13)70276-X
Goedert M. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 2015; 349(6248). doi: https://doi. org/10.1080/01677063.2017.1395425
Ghosh A. K, Osswald H. L. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease. Chem Soc Rev 2014; 43(19):6765-6813. doi: 10.1126/ science.1255555
Ran Y, Hossain F, Pannuti A, Lessard, C. B, Ladd G. Z, Jung, J. I, Golde T. E, et al. γ-Secretase inhibitors in cancer clinical trials are pharmacologically and function- ally distinct. EMBO Mol Med 2017; 9(7):950-966. doi: 10.1039/c3cs60460h.
Bastianetto S, Ménard C, Quirion R. Neuroprotec- tive action of resveratrol. Biochim Biophys Acta Mol Basis Dis 2015; 1852(6):1195-1201. doi:10.1016/j. bbadis.2014.09.011
Chen X. F, Zhang Y. W, Xu H, Bu G. Transcriptional regulation and its misregulation in Alzheimer’s disease. Mol Brain 2013; 6(1):1-9. doi:10.1186/1756-6606-6-44
Lee H. J, Ryu J. M, Jung Y. H, Lee S. J, Kim J. Y, Lee
S. H, Han H. J, et al. High glucose upregulates BACE1- mediated Aβ production through ROS-dependent HIF-1α and LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells. Sci Rep 2016; 6(1):1-15. doi:10.1038/ srep36746
Chen R. F, Zhang T, Sun Y. Y, Sun Y. M, Chen W. Q, Shi N, Sun X. J, et al. Oxygen-glucose deprivation regulates BACE1 expression through induction of autophagy in Neuro-2a/APP695 cells. Neural Regen Res 2015; 10(9):1433. doi: 10.4103/1673-5374.165511
Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Pro- teinopathy, oxidative stress and mitochondrial dysfunc-
tion: cross talk in Alzheimer’s disease and Parkinson’s disease. Drug Design Dev Ther 2017; 11:797. doi: 10.2147/DDDT.S130514
Shi Z. M, Han Y. W, Han X. H, Zhang K, Chang Y. N, Hu Z. M, Hong W, et al. Upstream regulators and downstream effectors of NF-κB in Alzheimer’s dis- ease. J Neurol Sci 2016; 366:127-134. doi:10.1016/j. jns.2016.05.022
Hwang C. J, Park M. H, Choi M. K, Choi J. S, Oh K. W, Hwang D. Y, Hong J. T, et al. Acceleration of amyloido- genesis and memory impairment by estrogen deficiency through NF-κB dependent beta-secretase activation in presenilin 2 mutant mice. Brain Behav Immun 2016; 53:113-122. doi:10.1016/j.bbi.2015.11.013
Marchal J. A, Lopez G. J, Peran M, Comino A, Del- gado J. R, García-García JA, Garcia M. A, et al. The impact of PKR activation: from neurodegeneration to cancer. FASEB J 2014; 28(5):1965-1974. doi:10.1096/ fj.13-248294
Paquet C, Dumurgier J, Hugon J. Pro-apoptotic kinase levels in cerebrospinal fluid as potential future biomark- ers in Alzheimer’s disease. Front Neurol 2015; 6:168. doi:10.3389/fneur.2015.00168
Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 patho- genic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Nat Acad Sci USA 2017; 114(4):E476-E485. doi:10.1073/ pnas.1618657114
Zhou Q, Wang M, Du Y, Zhang W, Bai M, Zhang Z, Miao J, et al. Inhibition of c-J un N-terminal kinase activation reverses Alzheimer disease phenotypes in APP swe/ PS 1dE 9 mice. Annals Neurol 2015; 77(4):637-654. doi:10.1002/ana.24361
Pohlkamp T, Wasser C. R, Herz J. Functional roles of the interaction of APP and lipoprotein receptors. Front Mol Neurosci 2017; 10:54. doi:10.3389/fnmol.2017.00054
Martiskainen H, Haapasalo A, Kurkinen K. M, Pihla- jamäki J, Soininen H, Hiltunen M. Targeting ApoE4/ ApoE receptor LRP1 in Alzheimer’s disease. Expert Opin Theur Targets 2013; 17(7):781-794. doi:10.1517/ 14728222.2013.789862
Xue-Shan Z, Qi W, Zhong R, Li-hong P, Zhi-han T, Zhi-sheng J, Lu-shan L, et al. Imbalanced cholesterol metabolism in Alzheimer’s disease. Clinica Chim Acta 2016; 456:107-114. doi:10.1016/j.cca.2016.02.024
Walker D, Lue L. F, Paul G, Patel A, Sabbagh M. N. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease. Expert Opin Invest Drugs 2015; 24(3):393-399. doi:10.1517/1 3543784.2015.1001490
Xu X. Y, Deng C. Q, Wang J, Deng X. J, Xiao Q, Li Y, Chen G. J, et al. Plasma levels of soluble receptor for advanced glycation end products in Alzheimer’s disease. Int J Neurosci 2017; 127(5):454-458. doi:10.1080/0020 7454.2016.1193861
Choi B. R, Cho W. H, Kim J, Lee H. J, Chung C, Jeon
W. K, Han J. S. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alz- heimer’s disease. Experimental & molecular medicine. 2014; 46(2):e75-e75. doi: https://doi.org/10.1038/ emm.2013.147
Chiarini A, Armato U, Liu D, Dal Prà I. Calcium-sensing receptors of human neural cells play crucial roles in Alzheimer’s disease. Front Physiol 2016; 7:134. doi: 10.3389/fphys.2016.00134
Zempel H, Mandelkow E. Lost after translation: mis- sorting of Tau protein and consequences for Alzhei- mer disease. Trends Neurosci 2014; 37(12):721-732. doi:10.1016/j.tins.2014.08.004
Khan S. S, Bloom G. S. Tau: the center of a signaling nexus in Alzheimer’s disease. Front Neurosci 2016; 10:31. doi:10.3389/fnins.2016.00031
Avila J, Pallas N, Bolós M, Sayas C. L, Hernandez F. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. Expert Opin Ther Targets 2016; 20(6):653-661. doi:10.1517/14728222.2016.1131269
Kadavath H, Hofele R. V, Biernat J, Kumar S, Tepper K, Urlaub H, Zweckstetter M, et al. Tau stabilizes microtu- bules by binding at the interface between tubulin heter- odimers. Proc Nat Acad Sci USA 2015; 112(24):7501- 7506. doi:10.1073/pnas.1504081112
Marti L, Latypova X, Wilson C. M, Magnaudeix A, Per- rin M. L, Yardin C, et al. Tau protein kinases: involve- ment in Alzheimer’s disease. Ageing Research Rev 2013; 12(1):289-309. doi:10.1016/j.arr.2012.06.003
Robert A, Liu Y, Nguyen M, Meunier B. Regulation of copper and iron homeostasis by metal chelators: A pos- sible chemotherapy for Alzheimer’s disease. Accounts Chem Res 2015; 48(5):1332-1339. doi:10.1021/acs.
accounts.5b00119
Lee H. J, Korshavn K. J, Kochi A, Derrick J. S, Lim M.
H. Cholesterol and metal ions in Alzheimer’s disease. Chem Soc Rev 2014; 43(19):6672-6682. doi: https://doi. org/10.1039/C4CS00005F
Griffin W. S, Stanley L. C, Ling C. H. E. N, White L, MacLeod V, Perrot L. J, Araoz C, et al. Brain in- terleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Nat Acad Sci USA 1989; 86(19):7611-7615. doi:10.1073/ pnas.86.19.7611
Rogers J, Luber-Narod J, Styren S. D, Civin W. H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol- ogy of aging. 1988; 9:339-349. doi: 10.1016/s0197- 4580(88)80079-4
Wyss-Coray T, Yan F, Lin A. H. T, Lambris J. D, Alexan- der J. J, Quigg, R. J, Masliah E. Prominent neurodegen- eration and increased plaque formation in complement- inhibited Alzheimer’s mice. Proceedings of the National Academy of Sciences. 2002; 99(16):10837-10842. doi: https://doi.org/10.1073/pnas.162350199
Beard C. M, Waring S. C, O’Brien P. C, Kurland L. T, Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. In Mayo Clinic Proceed- ings. Elsevier. 1998; 73(10):951-955. doi: https://doi. org/10.4065/73.10.951
Breitner J. C, Gau B. A, Welsh K. A, Plassman B. L, McDonald W. M, Helms M. J, Anthony J. C. Inverse association of anti–inflammatory treatments and Alz- heimer’s disease: initial results of a co–twin control study. Neurology 1994; 44(2): 227-227. doi:10.1212/ WNL.44.2.227
Rich JB, Rasmusson D. X, Folstein M. F, Carson K. A, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995; 45(1): 51-55. doi:10.1212/WNL.45.1.51
McGeer, P. L., & McGeer, E. G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical stud- ies. Neurobiol Aging 2007; 28(5):639-647. doi:10.1016/j. neurobiolaging.2006.03.013
McGeer, P. L., & Rogers, J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurol- ogy. 1992; 42(2):447-449. doi: 10.1212/wnl.42.2.447
Zotova, E., Nicoll, J. A., Kalaria, R., Holmes, C., & Bo- che, D. Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Res Ther. 2010; 2(1):1-9. doi: https://doi.org/10.1186/alzrt24
Kim, Y. S., Joh, T. H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 2006; 38(4):333- 347. doi:10.1038/ emm.2006.40
Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Don- nelly, R. J., Jacobsen, J. S, Gajdusek D. C, et al. Interleu- kin 1 regulates synthesis of amyloid beta-protein precur- sor mRNA in human endothelial cells. Proceedings of the National Academy of Sciences. 1989; 86(19):7606-7610. doi: https://doi.org/10.1073/pnas.86.19.7606
Plassman, B. L., Havlik, R. J., Steffens, D. C., Helms,
M. J., Newman, T. N., Drosdick, D., Breitner J. C, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 2000; 55(8):1158-1166. doi: https://doi.org/10.1212/ WNL.55.8.1158
Quintanilla, R. A., Orellana, D. I., González-Billault, C., Maccioni, R. B. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/ p35 pathway. Exp Cell Res 2004; 295(1):245-257. doi: https://doi.org/10.1016/j.yexcr.2004.01.002
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leis- gang, A. M., Salazar, A. M., Lamb, B. T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Demen: Transl Res Clin Interv 2018; 4:575-590. doi: 10.1016/j. trci.2018.06.014
Feng, YS., Tan, Z. X., Wu, L. Y., Dong, F., Zhang, F. The involvement of NLRP3 inflammasome in the treat- ment of Alzheimer’s disease. Ageing Res Rev 2020;101192. doi:10.1016/j.arr.2020.101192
Pennisi, M., Crupi, R., Di Paola, R., Ontario, M. L., Bella, R., Calabrese, E. J., Calabrese V, et al. Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease. J Neurosci Res 2017; 95(7):1360-1372. doi: https://doi.org/10.1002/jnr.23986
Guo, H., Callaway, J. B., Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeu- tics. Nat Med 2015; 21(7):677-687. doi: https://doi. org/10.1038/nm.3893
Walsh, J. G., Muruve, D. A., Power, C. Inflammasomes in
the CNS. Nature Reviews Neuroscience. 2014; 15(2):84-
doi: https://doi.org/10.1038/nrn3638
Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R. Inflammasomes in health and disease. Nature 2012; 481(7381):278-286. doi: https://doi.org/10.1038/na- ture10759
Thawkar, B. S., Kaur, G. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease. J Neuroimmunol 2019; 326:62-74. doi: https://doi.org/10.1016/j.jneu- roim.2018.11.010
Brydges, S. D., Broderick, L., McGeough, M. D., Pena,
C. A., Mueller, J. L., Hoffman, H. M. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 2013; 123(11):4695-4705. doi: 10.1172/ JCI71543
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Feldstein A. E, et al. NLRP3 inflammasome activation results in hepatocyte pyropto- sis, liver inflammation, and fibrosis in mice. Hepatology 2014; 59(3):898-910. doi:10.1002/hep.26592
Malik, A., & Kanneganti, T. D. Inflammasome activation and assembly at a glance. J Cell Sci 2017; 130(23):3955-3963. doi: 10.1242/jcs.207365
Bauernfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Latz E, et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183(2):787-791. doi:10.4049/ jimmunol.0901363
Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., Núñez, GK. efflux is the common trigger of NLRP3 inflammasome activa- tion by bacterial toxins and particulate matter. Immu- nity 2013; 38(6):1142-1153. doi:10.1016/ j.immuni.2013.05.016
Chen J, Chen Z. J. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature 2018; 564(7734):71-76. doi:10.1038/s41586- 018-0761-3
Samir P, Kesavardhana S, Patmore D. M, Gingras S, Ma- lireddi R. S, Karki R, Kanneganti T. D, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature 2019; 573(7775):590- 594. doi:10.1038/s41586-019-1551-2
Sharif, H., Wang, L., Wang, W. L., Magupalli, V. G., An- dreeva, L., Qiao, Q., Wu H, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature 2019; 570(7761):338-343. doi:10.1038/s41586- 019-1295-z
Afonina, I. S., Zhong, Z., Karin, M., Beyaert, R. Limiting inflammation—the negative regulation of NF-κB and the NLRP3 inflammasome. Nat Immunol 2017; 18(8):861. doi:10.1038/ni.3772
Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991;57(1):1-7. doi: 10.1055/s- 2006-960004.
Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The Indian solid gold. Adv Exp Med Biol 2007;595:1–75. doi:10.1007/978-0-387-46401-5_1
Wichitnithad W, Jongaroonngamsang N, Pummangura S, Rojsitthisak P. A simple isocratic HPLC method for the simultaneous determination of curcuminoids in commercial turmeric extracts. Phytochem Anal. 2009;20:314–319. doi: https://doi.org/10.1002/pca.1129
Shi X, Zheng Z, Li J, Xiao Z, Qi W, Zhang A, Wu Q, Fang
Y. Curcumin inhibits Aβ- induced microglial inflamma- tory responses in vitro: Involvement of ERK1/2 and p38 signaling pathways. Neurosci Lett 2015; 594:105-10. doi: 10.1016/j.neulet.2015.03.045.
Cianciulli A, Calvello R, Porro C, Trotta T, Salvatore R, Panaro MA. PI3k/Akt signalling pathway plays a crucial role in the anti-inflammatory effects of curcumin in LPS-activated microglia. Int Immunopathol 2016; 36:282-90. doi: 10.1016/j.intimp.2016.05.007.
Liu ZJ, Li ZH, Liu L, Tang WX, Wang Y, Dong MR, Xiao C. Curcumin Attenuates Beta- Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer’s Disease. Front Pharmacol 2016; 7:261. doi: 10.3389/fphar.2016.00261.
Sahebkar A, Cicero AF, Simental-Mendía LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta- analysis Of randomized controlled trials. Pharmacol Res 2016; 107:234-42. doi: 10.1016/j.phrs.2016.03.026.
Derosa G, Maffioli P, Simental-Mendía LE, Bo S, Sa- hebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016; 111:394-404. doi: 10.1016/j.phrs.2016.07.004.
Gibellini L, Bianchini E, De Biasi S, Nasi M, Cossarizza A, Pinti M. Natural Compounds Modulating Mitochon- drial Functions. Evid Based Complement Alternat Med 2015. doi: 10.1155/2015/527209.
Uğuz AC, Öz A, Nazıroğlu M. Curcumin inhibits apoptosis by regulating intracellular calcium re- lease, reactive oxygen species and mitochondrial depolarization levels in SHSY5Y neuronal cells. J Recept Signal Transduct Res 2016;36(4):395-401. doi: 10.3109/10799893.2015.1108337.
Fan CD, Li Y, Fu XT, Wu QJ, Hou YJ, Yang MF, Sun JY, Fu XY, Zheng ZC, Sun BL. Reversal of Beta-Amyloid- Induced Neurotoxicity in PC12 Cells by Curcumin, the Important Role of ROS-Mediated Signaling and ERK Pathway. Cell Mol Neurobiol. 2017;37(2):211-222. doi: 10.1007/s10571-016-0362-3.
Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta- amyloid fibrils in vitro. J Neurosci Res 2004;75(6):742- 50. doi: 10.1002/jnr.20025.
Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patients. J Alzheimers Dis. 2006;10(1):1-7. doi: 10.3233/JAD- 2006-10101.
Kim H, Park BS, Lee KG, Choi CY, Jang SS, Kim YH, Lee SE. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem. 2005;53(22):8537-41. doi: 10.1021/ jf051985c.
Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto
H. Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation. Neuroreport. 2008;19(13):1329-33. doi: 10.1097/WNR.0b013e32830b8ae1
Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007;102(4):1095-104. doi:10.1111/j.1471- 4159.2007.04613.x.
Wang YJ, Thomas P, Zhong JH, Bi FF, Kosaraju S, Pol- lard A, Fenech M, Zhou XF. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer’s disease mouse. Neurotox Res. 2009;15(1):3- 14. doi: 10.1007/s12640- 009-9000-x.
Voulgaropoulou, S. D., van Amelsvoort, T. A. M. J., Prickaerts, J., & Vingerhoets, C. The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain research. 2019; 1725:146476. doi: https://doi. org/10.1016/j.brainres.2019.146476.
Serafini, MM., Catanzaro, M., Rosini, M., Racchi, M., Lanni, C. Curcumin in Alzheimer’s disease: Can we think to new strategies and perspectives for this mole- cule? Pharmacol Res 2017. 124:146-155. doi: https:// doi.org/10.1016/j.phrs.2017.08.004
Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, Martins RN. Examin- ing the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s dis- ease. Br J Nutr 2016;115(3):449-65. doi: 10.1017/ S0007114515004687.
Arjomandi OK, Almasi S, Hosseinzadeh L, Kavoosi M and Adibi H. Preparation, Characterization and In Vitro Biological Evaluation of Novel Curcumin Derivatives as Cytotoxic and Apoptosis-Inducing Agents. Anti-Can- cer Agents Med Chem 2021. 21:1309-1322. doi: 10.2174/1871520620666201002111205
Baiji Xue , Jinxiang Huang , Haoxiang Zhang , Bingliang Li , Man Xu , Yuelan Zhang, et al.. Micronized curcumin fabricated by supercritical CO2 to improve antibacterial activity against Pseudomonas aeruginosa. Artif Cells Nanomed Biotechnol 2020;48:1,1135-1143. doi:10.10 80/21691401.2020.1815755
Braidy, N., Jugder, B. E., Poljak, A., Jayasena, T., Mo- hammad Nabavi, S., Sachdev, P., Grant, R. Molecular targets of tannic acid in Alzheimer’s disease. Curr Alz- heimer Res 2017; 14(8):861-869. doi:10.2174/1567205 014666170206163158
Sylla, T., Pouységu, L., Da Costa, G., Deffieux, D., Monti, J. P., & Quideau, S. Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibi- tory Activity on Alzheimer’s Amyloid β–Peptide Ag- gregation. Angewandte Chemie International Edition. 2015; 54(28):8217-8221. doi: https://doi.org/10.1002/ anie.201411606
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Frosch M. P, et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of disease. 2006; 24(3):516-524. doi:
https://doi.org/10.1016/j.nbd.2006.08.017
Mori, T., Rezai-Zadeh, K., Koyama, N., Arendash, G. W., Yamaguchi, H., Kakuda, N., Town T, et al. Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 2012; 287(9):6912-6927. doi: https://doi.org/10.1074/jbc.M111.294025
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Tan J, et al. Green tea epigallocat- echin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005; 25(38):8807-8814. doi: https://doi.org/10.1523/ JNEUROSCI.1521-05.2005
Menze, E. T., Esmat, A., Tadros, M. G., Abdel-Naim, A. B., Khalifa, A. E. Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties. PLoS One 2015; 10(2):e0117223. doi: 10.1371/journal.pone.0117223
Mazumder, M. A. R., Hongsprabhas, P. Genistein as antioxidant and antibrowning agents in in vivo and in vitro: A review. Biomed Pharmacother 2016; 82:379-392. doi: https://doi.org/10.1016/j.bi- opha.2016.05.023
Gong, DK., Liu, BH., Tan, XH. Genistein prevents cadmium-induced neurotoxic effects through its an- tioxidant mechanisms. Drug Res 2015; 65(02): 65-69. doi: 10.1055/s-0034-1372595
Soni, M., White, L. R., Kridawati, A., Bandelow, S., Hogervorst, E. Phytoestrogen consumption and risk for cognitive decline and dementia: with consideration of thyroid status and other possible mediators. The Journal of steroid biochemistry and molecular biol- ogy. 2016; 160:67-77. doi: https://doi.org/10.1016/j. jsbmb.2015.10.024
Liao, W., Jin, G., Zhao, M., Yang, H. The Effect of Genistein on the Content and Activity of α–and β– Secretase and Protein Kinase C in Aβ–Injured Hip- pocampal Neurons. Basic & clinical pharmacology & toxicology. 2013; 112(3):182-185. doi: https://doi. org/10.1111/bcpt.12009
Radi E, P. Formichi, C. Battisti, A. Federico, Apoptosis and oxidative stress in neurodegenerative diseases, Journal of Alzheimer’s Disease. 2014; S125-S152. doi: 10.3233/JAD-132738
Fazel Nabavi, S., Daglia, M., Tundis, R., Rosa Loizzo, M., Sobarzo-Sanchez, E., Erdogan Orhan, I., & Mo- hammad Nabavi, S. Genistein: A boon for mitigating ischemic stroke. Current topics in medicinal chemistry. 2015; 15(17):1714-1721. DOI: 10.2174/15680266156 66150427122709
Ahmed, T., Javed, S., Tariq, A., Onofrio, G., Daglia, M., Fazel Nabavi, S., & Mohammad Nabavi, S. Daidzein and its effects on brain. Current medicinal chemistry, 2017; 24(4):365-375. DOI: 10.2174/09298673236661 61101140214
Xi YD, Zhang, D. D., Ding, J., Yu, H. L., Yuan, L. H., Ma,
W. W, et al. Genistein inhibits Aβ25–35-induced syn- aptic toxicity and regulates CaMKII/CREB pathway in SH-SY5Y cells. Cell Mol Neurobiol 2016; 36(7):1151- 1159.doi:10.1007/s10571-015-0311-6
Bagheri, M., Rezakhani, A., Nyström, S., Turkina,
M. V., Roghani, M., Hammarström, P, et al. Amyloid beta 1-40-induced astrogliosis and the effect of gen- istein treatment in rat: a three-dimensional confocal morphometric and proteomic study. PLoS One 2013; 8(10):e76526. doi: 10.1371/journal.pone.0076526
Devi, K. P., Shanmuganathan, B., Manayi, A., Nabavi, S. F., & Nabavi, S. M. Molecular and therapeutic targets of genistein in Alzheimer’s disease. Molecular neurobiol- ogy. 2017; 54(9):7028-7041. doi: ttps://doi.org/10.1007/ s12035-016-0215-6
Henderson, V. W. Alzheimer’s disease: review of hor- mone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 2014; 142:99-106. doi: https://doi.org/10.1016/ j.jsbmb.2013.05.010
Bagheri, M., Joghataei, M. T., Mohseni, S., & Roghani,
M. Genistein ameliorates learning and memory deficits in amyloid β (1–40) rat model of Alzheimer’s disease. Neu- robiology of Learning and Memory. 2011; 95(3):270- 276. doi: https://doi.org/10.1016/j.nlm.2010.12.001
Wang, Y. Y., Zheng, W., Ng, C. H., Ungvari, G. S., Wei, W., Xiang, Y. T. Meta–analysis of randomized, double–blind, placebo–controlled trials of melatonin in Alzheimer’s disease. Int J Geriat Psychiatry 2017; 32(1):50-57. doi:10.1002/gps.4571
Miller, E., Morel, A., Saso, L., Saluk, J. Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders. Curr Topics Med Chem 2015; 15(2):163-169. DOI: 10.2174/15680266156661
Reiter, R. J., Tan, D. X., & Galano, A. Melatonin: ex- ceeding expectations. Physiology. 2014. doi: https://doi. org/10.1152/physiol.00011.2014
Perez, A., Li, T., Hernandez, S., Zhang, R., & Cao,
C. The rationale of using coffee and melatonin as an alternative treatment for alzheimer’s disease. J Alzhei- mers Dis Parkinsonism. 2016; 6(205):2161-0460. doi: 10.4172/2161-0460.1000205
Gunasingh Masilamoni, J., Philip Jesudason, E., Dhan- dayuthapani, S., Ashok, B. S., Vignesh, S., Jebaraj, W.
C. E., ... & Jayakumar, R. The neuroprotective role of melatonin against amyloid β peptide injected mice. Free radical research. 2008; 42(7):661-673. doi: https://doi. org/10.1080/10715760802277388
Ali, T., & Kim, M. O. Melatonin ameliorates amyloid beta–induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI 3/Akt/GS k3β pathway in the mouse hippocampus. Journal of pineal research. 2015; 59(1):47-59. doi: https://doi.org/10.1111/jpi.12238
Jaworek, J., Szklarczyk, J., Bonior, J., Kot, M., Góralska, M., Pierzchalski, P., ... & Tomaszewska, R. Melatonin metabolite, N (1)-acetyl-N (1)-formyl-5-methoxykynu- ramine (AFMK), attenuates acute pancreatitis in the rat: in vivo and in vitro studies. J Physiol Pharma- col 2016; 676:411. doi: 10.3390/ ijms18051014
Zhang, HM., Zhang, Y. Melatonin: a well–docu- mented antioxidant with conditional pro–oxidant ac- tions. J Pineal Res 2014; 57(2):131-146. doi: https:// doi.org/10.1111/jpi.12162
Kandalepas, P. C., Mitchell, J. W., & Gillette, M. U. Melatonin signal transduction pathways require E-box- mediated transcription of Per1 and Per2 to reset the SCN clock at dusk. 2016; 11(6):e0157824. DOI: 10.1371/ journal.pone.0157824
Waly, N. E., & Hallworth, R. Circadian pattern of me- latonin MT1 and MT2 receptor localization in the rat suprachiasmatic nucleus. Journal of circadian rhythms, 2015; 13. doi: 10.5334/jcr.ab
Kong, P. J., Byun, J. S., Lim, S. Y., Lee, J. J., Hong, S. J., Kwon, K. J., & Kim, S. S. Melatonin induces Akt phosphorylation through melatonin receptor-and PI3K- dependent pathways in primary astrocytes. Korean J Physiol Pharmacol 2008; 12(2):37. doi: 10.4196/ kjpp.2008.12.2.37
Muche, A., Bürger, S., Arendt, T., Schliebs, R. Hypoxic stress, brain vascular system, and β-amyloid: a primary cell culture study. Nutr Neurosci 2015; 18(1):1-11. doi: 10.1179/1476830513Z.000000000112
Shi, J., Tian, J., Zhang, X., Wei, M., Ni, J., Li, T., ... & Wang, P. P1–407: INFLUENCE OF GEPT EXTRACT ON HIPPOCAMPAL EXPRESSION OF CHOLINE ACETYLTRANSFERASE AND ACETYLCHO- LINESTERASE OF APP/PS1 TRANSGENIC MICE. Alzheimer’s & Dementia. 2014; 10:P462-P463. doi: https://doi.org/10.1016/j.jalz.2014.05.650
Cardinali, D. P., Vigo, D. E., Olivar, N., Vidal, M. F., & Brusco, L. I. Melatonin therapy in patients with Alzhei- mer’s disease. Antioxidants. 2014; 3(2):245-277. doi: https://doi.org/10.3390/antiox3020245
Lin, L., Huang, Q. X., Yang, S. S., Chu, J., Wang, J. Z., & Tian, Q. Melatonin in Alzheimer’s disease. Interna- tional journal of molecular sciences. 2013; 14(7): 14575- 14593. doi: https://doi.org/10.3390/ijms140714575
Revilla, S., Suñol, C., García-Mesa, Y., Giménez-Llort, L., Sanfeliu, C., & Cristòfol, R. Physical exercise im- proves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. Neurophar- macology. 2014; 81:55-63. doi: https://doi.org/10.1016/j. neuropharm.2014.01.037
Cohen-Mansfield, J., Garfinkel, D., Lipson, S. Melatonin for treatment of sundowning in elderly persons with dementia – a preliminary study. Arch Gerontol Geriatr 2000; 31(1):65-76. doi:10.1016/S0167-4943(00)00068- 6
Fainstein, I., Bonetto, A. J., Brusco, L. I., Cardinali, D.
P. Effects of melatonin in elderly patients with sleep dis- turbance: a pilot study. Curr Ther Res 1997; 58(12):990- 1000. doi:10.1016/S0011-393X(97)80066-5
Mahlberg, R., Kunz, D., Sutej, I., Kühl, K. P., & Hellweg, R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psy- chopharmacol 2004; 24(4):456-459. doi: 10.1097/01. jcp.0000132443.12607.fd
Mahlberg, R., & Walther, S. Actigraphy in agitated patients with dementia. Zeitschrift Gerontol Geriatrie 2007; 40(3):178-184. doi:10.1007/s00391-007-0420-z
Furio, A. M., Brusco, L. I., Cardinali, D. P. Possible ther- apeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res 2007; 43(4):404-409.
doi:10.1111/j.1600-079X.2007.00491.x
Vingtdeux, V., Dreses-Werringloer, U., Zhao, H., Davies, P., & Marambaud, P. Therapeutic potential of resveratrol in Alzheimer’s disease. BMC Neurosci 2008; 9(2):1-5. doi:10.1186/1471-2202-9-S2-S6
Ahmed T, Javed, S., Javed, S., Tariq, A., Šamec, D., Tejada, S., et al. Resveratrol and Alzheimer’s disease: mechanistic insights. Mol Neurobiol 2017; 54(4):2622- 2635. doi:10.1007/s12035-016-9839-9
Fu, Z., Aucoin, D., Ahmed, M., Ziliox, M., Van Nostrand, W. E., & Smith, S. O. Capping of Aβ42 oligomers by small molecule inhibitors. Biochemistry. 2014; 53(50):7893-7903. doi: https://doi.org/10.1021/ bi500910b
Ghobeh, M., Ahmadian, S., Meratan, A. A., Ebrahim– Habibi, A., Ghasemi, A., Shafizadeh, M., Nemat-Gor- gani, M. Interaction of Aβ (25–35) fibrillation products with mitochondria: Effect of small-molecule natural products. Peptide Sci 2014; 102(6):473-486. doi: https:// doi.org/10.1002/bip.22572
Ribeiro, C. A., Saraiva, M. J., Cardoso, I. Stability of the transthyretin molecule as a key factor in the inter- action with A-beta peptide-relevance in Alzheimer’s disease. PloS one 2012; 7(9):e45368. doi: https://doi. org/10.1371/journal.pone.0045368
Ge, J. F., Qiao, J. P., Qi, C. C., Wang, C. W., Zhou, J. N. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int 2012; 61(7):1192-1201. doi: https:// doi.org/10.1016/j.neuint.2012.08.012
Ladiwala, A. R. A., Lin, J. C., Bale, S. S., Marcelino- Cruz, A. M., Bhattacharya, M., Dordick, J. S., & Tessier, P. M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. Journal of Biological Chemistry. 2010; 285(31):24228-24237. doi: https://doi.org/10.1074/ jbc.M110.133108
He, X. P., Deng, Q., Cai, L., Wang, C. Z., Zang, Y., Li, J., Tian, H, et al. Fluorogenic resveratrol-confined graphene oxide for economic and rapid detection of Alzheimer’s disease. ACS applied materials & interfaces. 2014; 6(8):5379-5382. doi: https://doi.org/10.1021/am5010909
Patil, S. P., Tran, N., Geekiyanage, H., Liu, L., Chan, C. Curcumin-induced upregulation of the anti-tau cochap- erone BAG2 in primary rat cortical neurons. Neurosci Lett 2013; 554:121-125. doi: https://doi.org/10.1016/j. neulet.2013.09.008
Zhao YN, Li, W F., Li, F., Zhang, Z., Dai, YD., Xu, AL, et al. Resveratrol improves learning and memory in normally aged mice through microRNA-CREB path- way. Biochem Biophys Res Commun 2013; 435(4):597-602. doi:10.1016/j.bbrc.2013.05.025
Mei, Y., Jiang, C., Wan, Y., Lv, J., Jia, J., Wang, X., Tong Z, et al. Aging–associated formaldehyde–induced norepinephrine deficiency contributes to age–related memory decline. Aging cell. 2015; 14(4):659-668. doi: https://doi.org/10.1111/acel.12345
Moorthi, P., Premkumar, P., Priyanka, R., Jayachandran,
K. S., & Anusuyadevi, M. Pathological changes in hip- pocampal neuronal circuits underlie age-associated neu- rodegeneration and memory loss: positive clue toward SAD. Neuroscience. 2015; 301:90-105. doi: https://doi. org/10.1016/j.neuroscience.2015.05.062
Wight, R. D., Tull, C. A., Deel, M. W., Stroope, B. L., Eubanks, A. G., Chavis, J. A., Hensley L. L, et al. Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. Biochemical and biophysi- cal research communications. 2012; 426(1):112-115. doi: https://doi.org/10.1016/j.bbrc.2012.08.045
Yao, Y., Li, J., Niu, Y., Yu, J. Q., Yan, L., Miao, Z. H., Li,
W. Q, et al. Resveratrol inhibits oligomeric Aβ-induced microglial activation via NADPH oxidase. Mol Med Rep 2015; 12(4):6133-6139. doi: https://doi.org/10.3892/ mmr.2015.4199
Kim, Y., Lim, S. Y., Rhee, S. H., Park, K. Y., Kim, C. H., Choi, B. T., Choi Y. H, et al. Resveratrol inhibits induc- ible nitric oxide synthase and cyclooxygenase-2 expres- sion in β-amyloid-treated C6 glioma cells. International journal of molecular medicine. 2006; 17(6):1069-1075. doi: https://doi.org/10.3892/ijmm.17.6.1069
Zhang, Y., Dong, R., Yang, Q., Zhang, L., Li, J., & Zhao,
H. (2019). [Resveratrol upregulates the gene and protein expressions of N-methyl-D-aspartate receptor 1 and pro- tein kinase C in the hippocampus in Alzheimer’s disease rats]. Journal of Hygiene Research, 48(2), 269–278. https://europepmc.org/article/med/31133106
Huang, T. C., Lu, K. T., Wo, Y. Y. P., Wu, Y. J., & Yang,
Y. L. Resveratrol protects rats from Aβ-induced neuro- toxicity by the reduction of iNOS expression and lipid peroxidation. 2011; 6(12):e29102. doi: 0.1371/journal. pone.0029102
Granzotto, A., & Zatta, P. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity.
; 6(6):e21565. doi: 10.1371/journal.pone.0021565
Kwon, K. J., Kim, H. J., Shin, C. Y., & Han, S. H. Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegen- eration by modulating AMP-activated protein kinase pathways. Journal of clinical neurology. 2010; 6(3):127. doi: 10.3988/jcn.2010.6.3.127
Koukoulitsa C, Villalonga-Barber, C., Csonka, R., Alexi, X., Leonis, G., Dellis, D, et al. Biological and computa- tional evaluation of resveratrol inhibitors against Alzhei- mer’s disease. J Enz Inhib Med Chem 2016; 31(1):67-77. doi: 10.3109/14756366.2014.1003928
Jang, J. H., Surh, Y. J. Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death. Free Rad Biol Med 2003; 34(8):1100-1110. doi: https://doi. org/10.1016/s0891-5849(03)00062-5
D Rege, S., Geetha, T., L Broderick, T., & Ramesh Babu,
J. Resveratrol protects β amyloid-induced oxidative damage and memory associated proteins in H19-7 hip- pocampal neuronal cells. Current Alzheimer Research. 2015; 12(2):147-156. doi: https://doi.org/10.1007/ s12035-016-9839-9
Braidy, N., Jugder, B. E., Poljak, A., Jayasena, T., Man- sour, H., Mohammad Nabavi, S., Grant R, et al. Resvera- trol as a potential therapeutic candidate for the treatment and management of Alzheimer’s disease. Current topics in medicinal chemistry. 2016; 16(17):1951-1960. DOI: 10.2174/1568026616666160204121431
Jeon, B. T., Jeong, E. A., Shin, H. J., Lee, Y., Lee, D. H., Kim, H. J., Roh G. S, et al. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012; 61(6):1444-1454. doi:10.2337/ db11-1498
Toth P, Tarantini, S., Tucsek, Z., Ashpole, N. M., Sos- nowska, D., Gautam, T, et al. Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and downregulation of NADPH oxidase. Am J Physiol Heart Circ Physiol 2014; 306(3), H299:H308. doi:10.1152/ ajpheart.00744.2013
Higashida K, Kim, S. H., Jung, S. R., Asaka, M., Hol- loszy, J. O., Han, DH. Effects of resveratrol and SIRT1 on PGC-1α activity and mitochondrial biogenesis: a reevaluation. PLoS Biol. 2013; 11(7):e1001603. doi: 10.1371/journal.pbio.1001603
Singh, J. C. H., Kakalij, R. M., Kshirsagar, R. P., Kumar,
B. H., Komakula, S. S. B., & Diwan, P. V. Cognitive effects of vanillic acid against streptozotocin-induced neurodegeneration in mice. Pharmaceutical biology. 2015; 53(5):630-636. doi: https://doi.org/10.3109/138 80209.2014.935866
Amin, F. U., Shah, S. A., & Kim, M. O. Vanillic acid at- tenuates Aβ 1-42-induced oxidative stress and cognitive impairment in mice. Scientific reports. 2017; 7(1):1-15. doi: https://doi.org/10.1038/srep40753
Villareal, M. O., Sasaki, K., Margout, D., Savry, C., Al- maksour, Z., Larroque, M., & Isoda, H. Neuroprotective effect of Picholine virgin olive oil and its hydroxycinnamic acids component against β-amyloid-induced toxicity in SH-SY5Y neurotypic cells. Cytotechnology 2016; 68(6):2567-2578. doi:10.1007/s10616-016-9980-3
Wang, Y., Wang, Y., Li, J., Hua, L., Han, B., Zhang, Y., et al. Effects of caffeic acid on learning deficits in a model of Alzheimer’s disease. Int J Mol Med 2016; 38(3):869- 875. doi: https://doi.org/10.3892/ijmm.2016.2683
Chao, X. J., Chen, Z. W., Liu, A. M., He, X. X., Wang,
S. G., et al. Effect of Tacrine–3–caffeic Acid, A Novel Multifunctional Anti–Alzheimer’s Dimer, Against Oxida- tive–Stress–Induced Cell Death in HT 22 Hippocampal Neurons: Involvement of Nrf2/HO–1 Pathway. CNS Neu- rosci Ther 2014; 20(9):840-850. doi:10.1111/cns.12286
Cai, Z., Wang, C., Yang, W. Role of berberine in Alzhei- mer’s disease. Neuropsychiatric disease and treatment. 2016; 12:2509. doi: 10.2147/NDT.S114846
Haghani, M., Shabani, M., & Tondar, M. The therapeutic potential of berberine against the altered intrinsic proper- ties of the CA1 neurons induced by Aβ neurotoxicity. European journal of pharmacology. 2015; 758, 82-88. doi: https://doi.org/10.1016/j.ejphar.2015.03.016
Jia, L., Liu, J., Song, Z., Pan, X., Chen, L., Cui, X., & Wang, M. Berberine suppresses amyloid–beta–in- duced inflammatory response in microglia by inhibit- ing nuclear factor–kappaB and mitogen–activated protein kinase signalling pathways. J Pharm Phar- macol 2012; 64(10):1510-1521. doi:10.1111/j.2042- 7158.2012.01529.x
Yu, G., Li, Y., Tian, Q., Liu, R., Wang, Q., Wang, J. Z, et al. Berberine attenuates calyculin A-induced cytotoxic-
ity and Tau hyperphosphorylation in HEK293 cells. J Alzheimer’s Dis 2011; 24(3):525-535. doi: 10.3233/ JAD-2011-101779
Luo, T., Jiang, W., Kong, Y., Li, S., He, F., Xu, J, et al. The protective effects of jatrorrhizine on β-amyloid (25-35)-induced neurotoxicity in rat cortical neurons. CNS Neurol Disor-Drug Targets 2012; 11(8):1030-1037. doi: https://doi.org/10.2174/187152712804870928
de Oliveira JS., Abdalla, F. H., Dornelles, G. L., Ade- fegha, S. A., Palma, T. V., Signor, C, et al. Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer’s-like dementia: involvement of acetylcholinesterase and cell death. Neurotoxicology 2016; 57:241-250. doi: https:// doi.org/10.1016/j.neuro.2016.10.008
Huang, M., Jiang, X., Liang, Y., Liu, Q., Chen, S., & Guo,
Y. I. Berberine improves cognitive impairment by pro- moting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer’s disease. Experimental gerontology. 2017; 91:25-33. doi: https://doi.org/10.1016/j.exger.2017.02.004
Taylor, D. The pharmaceutical industry and the future of drug development, 2015. doi: 10.1039/9781782622345- 00001
Hara, T. (2003). Innovation in the pharmaceutical indus- try : the process of drug discovery and development. 271. https://www.e-elgar.com/shop/gbp/innovation-in-the- pharmaceutical-industry-9781843760504.html
Hu, X. Filing Patent Applications. In Smoothing a Criti- cal Transition. Springer, Singapore. 2020; 87-100) doi: https://doi.org/10.1007/978-981-15-4035-6_8
Sambamurti, K., Greig, N. H., Utsuki, T., Barnwell,
E. L., Sharma, E., Mazell, C., ... & Pappolla, M. A. Targets for AD treatment: conflicting messages from γ–secretase inhibitors. Journal of neurochemistry. 2011; 117(3):359-374. doi: https://doi.org/10.1111/j.1471- 4159.2011.07213.x
Saxena, U. Alzheimer’s disease amyloid hypothesis at crossroads: where do we go from here?. Expert opinion on therapeutic targets. 2010; 14(12):1273-1277. doi: https://doi.org/10.1517/14728222.2010.528285
Ji HF, Zhang HY. Multipotent natural agents to combat Alzheimer’s disease. Functional spectrum and structural features 1. Acta Pharmacol Sinica 2008; 29(2):143-151. doi:10.1111/j.1745-7254.2008.00752.x
Mecocci, P., Tinarelli, C., Schulz, R. J., Polidori, M. C. Nutraceuticals in cognitive impairment and Alzheimer’s disease. Front Pharmacol 2014; 5:147. doi: https://doi.
org/10.3389/fphar.2014.00147
Polidori, M. C. Preventive benefits of natural nutrition and lifestyle counseling against Alzheimer’s disease onset. J Alzheimer’s Dis 2014; 42(s4):S475-S482. doi: 10.3233/JAD-141539
Behnam, D.; Hayward, M.A. Resveratrol solubilisa- tion product for pharmaceutical purposes. WO Patent 2017215791A1. December 21, 2017.
Rosen G.S. Multi-component formulations for the treat- ment of cognitive decline including Alzheimer’s disease. US Patent 9682048B1. June 20, 2017.
Mathisen J.S.; Mathisen, H. A marine oil formulation comprising resveratrol or derivatives thereof for use in treating, delaying and/or preventing alzheimer’s disease. CA Patent 2914767A1. December 18, 2014.
Baraona RM, Sepúlveda, L.Q.; Saavedra, I.S.; Salas, R.S.; Salas, V.S. Nutraceutical composition that com- prises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing. US Patent 20120269794A1. July 22, 2014.
DiMauro, T.M. Methylene blue-curcumin analog for the treatment of Alzheimer’s Disease. US Patent 7906643B2. March 15 2011.
DiMauro, T.M. Use of nitrogen-containing curcumin ana- logs for the treatment alzheimer’s disease. July 01, 2010.
Helson, L.; Chiu, S.; Intravenous curcumin and deriva- tives for treatment of neurodegenerative and stress dis- orders. US Patent 9393198B2. July 19, 2016.
Mathisen, J.S.; Mathisen, H. Method of treating, delay- ing and/or preventing Alzheimer’s disease. US Patent 20150031653A1. August 01, 2017.
Bienkiewicz, E.A. Treating Amyloidoses With AVitamin B12 Composition Including Melatonin, Resveratrol, and EGCG. US Patent 20150065449A1. March 05, 2015.
Zhang, S. Hybrid compounds of curcumin and melatonin as neuroprotectants for neurodegenerative disorders. US Patent 9738605B2. August 22, 2017.
Khandelwal, S.; Omray, P.; Tripathi V.K. A bio-stabilized resveratrol formulation. WO Patent 2012017451A1. February 09, 2012.
Rongbiao, P, Xiaojuan, C, Xixin, H, Zhiyi, C, Yilin, Y, Yifan, H, et al. Tacrine-caffeic acid heteroblends, their preparation method and medicinal compositions. CN Patent 102617465A. August 01, 2012.
Siva, M.L.; Durairajan, S.K.; Liu, L.; Jiahong, L.U.
Berberine alkaloid as a medicament for prevention and treatment of neural disease. US Patent 20130237556A1. September 12, 2013.
Yong, D.; Zhenghuai, T.; Xiaoming, Q.; Wen, Y.; Zhi- pei, S.; Qiang, L.; Yan L. Genistein alkylamine com- pound, preparation method and use thereof. WO Patent 2014111028A1. July 24, 2014.
Liu L. Berberine salts, ursodeoxycholic salts and combi- nations, methods of preparation and application thereof. EP Patent 3174874A1. September 02, 2020.
Theoharis C. Anti-inflammatory compositions for treat- ing neuro-inflammation, US Patent 20130115202A1. May 09. 2013.
Weinberg, R.P.; Rha, C.; Sinskey, A.J.; Tan Y.A.; Sam- banthamurthi, R. Protective effects of oil palm compo- sition on alzheimer’s disease. EP Patent 3057437A1. October 07, 2020.
Frautschy, S.A.; Cole, G.M. Bioavailable curcuminoid formulations for treating Alzheimer’s disease and other age-related disorders. US Patent 9192644B2. November 24, 2015.
Gokaraju, G.R.; Gokaraju, R.R.; Golakoti, T.; Chirravuri, V.R.; Bhupathiraju, V. Nutraceutical composition from Garcinia mangostana. US Patent 8853261B2. October 07, 2014.
Perry, S.C. Composition to retard the onset of symptoms of alzheimer’s disease. US Patent 8021701B1. Septem- ber 20, 2011.
Duong, P., Tenkorang, M. A., Trieu, J., McCuiston, C., Rybalchenko, N., & Cunningham, R. L. Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment. Biol Sex Differences 2020; 11:1-18. doi: https://doi.org/10.1186/s13293-020-0283-1
Noguchi-Shinohara M, Ono K, Hamaguchi T, Nagai T, Kobayashi S, Komatsu J, Samuraki-Yokohama M, et al. Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzhei- mer’s disease progression. Sci Rep 2020;10(1):1-0. doi: 10.1038/s41598-020-73729-2
Frohlich J, Chaldakov GN, Vinciguerra M. Cardio- and neurometabolic adipobiology. Consequences and impli- cations for therapy. Int J Mol Sci 2021; 22:4137. doi: 10.3390/ijms22084137
Yanev S, Aloe L, Fiore F, Chaldakov GN. Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: Linking cardiometa- bolic and neuropsychiatric diseases. World J Pharmacol 2013; 2: 92-99. doi:10.5497/wjp.v2.i4.92
Email this article (Login required) 
